Browsing Tag
Jakafi
4 posts
Incyte stock in focus as $2bn Star Therapeutics deal nears for blood disorder pipeline
Incyte may buy Star Therapeutics for up to $2B. See why the deal matters for Jakafi risk and hematology growth.
Lilly bets up to $2.3bn on Ajax Therapeutics to crack the resistant myelofibrosis market with a Type II JAK2 inhibitor
Lilly is paying up to $2.3B for Ajax Therapeutics' Type II JAK2 inhibitor. The real question is whether it can crack Incyte's Jakafi grip on myelofibrosis.
Myelofibrosis breakthrough? Incyte’s INCA033989 delivers clinical and molecular wins
Incyte’s mutCALR antibody shows promise in myelofibrosis and ET. Find out what ASH 2025 data reveals about INCA033989’s future potential.
Vanda Pharmaceuticals’ VGT-1849A gets orphan drug designation for polycythemia vera treatment
Vanda Pharmaceuticals Inc. has achieved a critical regulatory milestone with the U.S. Food and Drug Administration (FDA) granting…